Neuchatel, Switzerland-based Masimo announces the CE marking and commercial launch in Europe of the single-patient-use adhesive rainbowSuperSensor, compatible for use with both Masimo and third-party monitors with Masimo rainbow technology inside. The comprehensive, convenient, and multi-purpose SuperSensor uses 12 LEDs to simultaneously offer 12 blood constituent parameters noninvasively and continuously.
These include: SET oxygen saturation (SpO2), total hemoglobin, SpHb, carboxyhemoglobin (SpCO), methemoglobin (SpMet), oxygen reserve index (ORi), PVi, RPVi, pulse rate (PR), respiration rate (RRp), perfusion index (Pi), fractional oxygen saturation (SpfO2), and oxygen content (SpOC), and are all on the same single-patient-use adhesive sensor. By allowing clinicians to noninvasively and continuously monitor so many different physiologic indicators simultaneously, the SuperSensor offers the ability to assess the patient’s status continuously.
At the core of the SuperSensor is Masimo SET pulse oximetry, which has been clinically proven to help care teams enhance patient safety and improve patient outcomes. More than 100 independent and objective studies reportedly have shown Masimo SET outperforms other pulse oximetry technologies in clinical settings and motion and low perfusion conditions — providing clinicians with increased sensitivity and specificity to make critical care decisions.
SET has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates, improve CCHD screening in newborns, and, when used for continuous monitoring with Masimo Patient SafetyNet in post-surgical wards, reduce deaths due to opioid overdose. It also has been shown to reduce rapid response team activations, ICU transfers, and the cost of care.
Continuous hemoglobin monitoring with SpHb as part of patient blood management programs has been found to help clinicians improve outcomes in both high- and low- blood loss surgeries, such as reducing the percentage of patients receiving transfusions, reducing the units of red blood cells transfused per patient, reducing the time to transfusion, and reducing costs. The utility of PVi, a measure of the dynamic changes in perfusion index that occur during the respiratory cycle, as an indicator of fluid responsiveness, has been demonstrated in more than 100 independent studies. According to Masimo, use of SpHb and PVi together, as part of an integrated goal-directed therapy protocol for fluid management and blood administration, has been shown to help clinicians reduce mortality 30 and 90 days after surgery, by 33% and 29%, respectively.
SpMet helps clinicians noninvasively and continuously monitor methemoglobin levels in the blood. Elevated methemoglobin levels can be caused by many drugs given in hospitals, including inhaled nitric oxide (iNO) therapy, which has been used as a potential treatment for lung complications associated with COVID-19. SpMet may be an important monitoring tool during iNO therapy.
“Critically ill patients are frequently hemodynamically unstable, with variable oxygen delivery, which may be inadequate and lead to a cumulative oxygen debt, especially with noradrenaline infusions,” says Max Jonas, MD, consultant in Intensive Care Medicine and Anesthesia at University Hospitals, Southampton, UK.”Clinically this makes continuous monitoring and optimization of oxygen delivery using hemoglobin, fluid responsiveness, and oxygen saturation extremely important. It is also clinically invaluable being able to recognize impaired oxygen carriage, and hence content in the blood, for instance the methemoglobinemia generated by inhaled nitric oxide therapy, which we are currently frequently using during the treatment of COVID-19 pneumonitis and also for pulmonary hypertension.”
